AC
PBLA

Armistice Capital’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Armistice Capital’s Portfolio PBLA Stock Details PBLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-91
Closed -$588K – 258
2022
Q3 		$588K Buy
+91
New +$1.91M 0.01% 148

Other funds holding PBLA

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFG
Oxford Financial Group Carmel, Indiana $1.97B AUM 22.31% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Armistice Capital's PBLA Position: Q4 2022 in Review

Armistice Capital sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q4 2022, closing a stake of 91 shares — an estimated $588K sold.

Armistice Capital first reported a position in PBLA in Q3 2022 and held it in 1 quarter. The position peaked at $588K in Q3 2022. 10 funds tracked by Wall St. Rank hold PBLA as of Q4 2022.

  • Armistice Capital reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Armistice Capital sold 91 Panbela Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $588K.
  • Armistice Capital first reported a position in Panbela Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Armistice Capital's Panbela Therapeutics, Inc. Common Stock position peaked at $588K in Q3 2022.
  • 10 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Armistice Capital's 13F filing for Q4 2022, filed 14 Feb 2023.